Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

This study has been completed.
Sponsor:
Collaborators:
Novartis Pharmaceuticals
Sanofi
Walther Cancer Institute
Information provided by:
Hoosier Cancer Research Network
ClinicalTrials.gov Identifier:
NCT00216112
First received: September 12, 2005
Last updated: April 28, 2011
Last verified: April 2011